Related Experiment Video
Updated: Jun 26, 2025

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides
Published on: September 16, 2020
The mitochondrial uncoupler 2,4-dinitrophenol modulates inflammatory and oxidative responses in Trypanosoma
José Edson Caetano-da-Silva1, Elda Gonçalves-Santos2, Elisa L B C Domingues2
1Programa de Pós-Graduação em Ciências Biológicas, Universidade Federal de Alfenas, Alfenas, 37130-001, Minas Gerais, Brazil.
Abstract:
By uncoupling oxidative phosphorylation, 2,4-dinitrophenol (DNP) attenuates reactive oxygen species (ROS) biosynthesis, which are known to aggravate infectious myocarditis in Chagas disease. Thus, the impact of DNP-based chemotherapy on Trypanosoma cruzi-induced acute myocarditis was investigated. C56BL/6 mice uninfected and infected untreated and treated daily with 100 mg/kg benznidazole (Bz, reference drug), 5 and 10 mg/kg DNP by gavage for 11 days after confirmation of T. cruzi infection were investigated. Twenty-four hours after the last treatment, the animals were euthanized and the heart was collected for microstructural, immunological and biochemical analyses. T. cruzi inoculation induced systemic inflammation (e.g., cytokines and anti-T. cruzi IgG upregulation), cardiac infection (T. cruzi DNA), oxidative stress, inflammatory infiltrate and microstructural myocardial damage in untreated mice. DNP treatment aggravated heart infection and microstructural damage, which were markedly attenuated by Bz. DNP (10 mg/kg) was also effective in attenuating ROS (total ROS, H2O2, and O2-), nitric oxide (NO), lipid (malondialdehyde - MDA) and protein (protein carbonyl - PCn) oxidation, TNF, IFN-γ, IL-10, and MCP-1/CCL2, anti-T. cruzi IgG, cardiac troponin I levels, as well as inflammatory infiltrate and cardiac damage in T. cruzi-infected mice. Our findings indicate that DNP aggravated heart infection and microstructural cardiomyocytes damage in infected mice. These responses were related to the antioxidant and anti-inflammatory properties of DNP, which favors infection by weakening the pro-oxidant and pro-inflammatory protective mechanisms of the infected host. Conversely, Bz-induced cardioprotective effects combined effective anti-inflammatory and antiparasitic responses, which protect against heart infection, oxidative stress, and microstructural damage in Chagas disease.
Insights
2,4-dinitrophenol (DNP) worsened Chagas disease myocarditis by suppressing protective inflammation, while benznidazole (Bz) offered cardioprotection. DNP
Area of Science:
- Cardiovascular Research
- Infectious Diseases
- Pharmacology
Background:
- Chagas disease, caused by Trypanosoma cruzi, leads to infectious myocarditis.
- Reactive oxygen species (ROS) exacerbate myocarditis.
- 2,4-dinitrophenol (DNP) uncouples oxidative phosphorylation, reducing ROS.
Purpose of the Study:
- To investigate the impact of DNP-based chemotherapy on Trypanosoma cruzi-induced acute myocarditis.
- To compare DNP's efficacy against benznidazole (Bz), a reference drug.
Main Methods:
- C56BL/6 mice were infected with T. cruzi.
- Mice received daily treatments of benznidazole (Bz) or DNP for 11 days.
- Cardiac tissues were analyzed for microstructural, immunological, and biochemical changes.
Main Results:
- DNP treatment aggravated heart infection and microstructural damage, despite reducing oxidative stress markers.
- Benznidazole (Bz) markedly attenuated heart infection and cardiac damage.
- DNP demonstrated antioxidant and anti-inflammatory effects, potentially favoring parasite survival.
Conclusions:
- DNP exacerbated T. cruzi-induced myocarditis by suppressing host defense mechanisms.
- Bz provided cardioprotection through combined anti-inflammatory and antiparasitic effects.
- DNP's utility in Chagas disease myocarditis requires further investigation due to its detrimental impact on infection.
More Related Videos
11:26Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer
Published on: February 13, 2019
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025